For its second fiscal quarter (ending June 30), NovoCure Ltd (NASDAQ: NVCR) has reported E.P.S. of $-0.31 compared to $-0.54 a year ago. This performance was $0.09 better than the consensus estimate of $-0.40. E.P.S. were $-1.58 for the latest four quarters through June 30 versus $-1.65 for the same period a year ago.
Recent Price Action
On 7/25/24, NovoCure Ltd (NASDAQ: NVCR) stock declined slightly by -0.7%, closing at $18.65. Moreover, this decline was accompanied by above average trading volume at 133% of normal. The stock has declined -2.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, NVCR is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. NovoCure has a very low Appreciation Score of 8 but a very high Power Rating of 86, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment